You can buy or sell BioScrip and other stocks, options, ETFs, and crypto commission-free!
BioScrip, Inc. engages in the provision of home infusion and home care management solutions. It partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. Read More The company was founded in 1996 and is headquartered in Denver, CO.
52 Week High
52 Week Low
HC Group Holdings III, Inc. -- Moody's places HC Group Holding's ratings under review for upgrade following the announced merger with BioScrip
HC Group Holdings III, Inc. -- Moody's places HC Group Holding's ratings under review for upgrade following the announced merger with BioScrip...
BioScrip's stock extends plunge after merger terms disappoint, but analyst recommends remaining bullish
Shares of BioScrip Inc. BIOS, -15.83% tumbled 9.0% toward a 9-month low in midday trade Monday, extending the sharp reversal suffered early in the previous session as investors digested the terms of the company's merger deal with Option Care Enterprises Inc. On Friday, the stock soared as much as 71% in premarket trade, and as much as 8.0% during the regular session, before pulling a sharp U-turn to close down 20.3%. Canaccord Genuity analyst Richard Close said that investors may have to suffer some short-t...
Yahoo FinanceMar 18
BioScrip (BIOS) Reports Loss in Q4, Both Margins Contract
BioScrip Inc. BIOS reported a loss from continuing operations of 14 cents per share for fourth-quarter 2018, wider than the Zacks Consensus Estimate. The figure deteriorated from the year-ago loss of 3 cents. At the end of 2018, loss from continuing operations was 49 cents a share, narrower than the year-ago loss of 59 cents. Revenues Net revenues of $183.6 million in the fourth quarter rose 0.5% year over year. This figure however missed the Zacks Consensus Estimate of $188 million. For the ful...
-$0.03 per share
-$0.14 per share